Who We Are

We are an innovative pre-clinical contract services, products & licensing company. Our mission is to use cutting-edge gene-editing technologies to accelerate pre-clinical research and drug development.

Using our gene editing tools, Hera built the SRG™ platform, a double knockout Sprague-Dawley rat engineered for T-cell, B-cell, and NK cell deficiency. Our first SRG model is the SRG OncoRat®, larger and a valuable complement and in some cases alternative to oncology studies in mice, OncoRat is uniquely suited for xenograft oncology studies given its excellent tumor take-rates and smooth transition from efficacy to safety. Animal studies are conducted by our experienced staff in our on-site vivarium that features a dual HEPA-filtered, disposable IVC rodent caging system.

We’re continuing to use our proprietary Cas-CLOVER CRISPR system and piggyBac gene-editing technologies and know-how to expand our robust pipeline of models and services. Our current animal models creation efforts are supporting immuno-oncology with a humanized SRG Model – the ImmunoRat™ and in pharmacology and toxicology with a humanized hepatocyte SRG Model – HepatoRat™.

Our History

2015–2016
Hera spun-out of Transposagen. Licenses obtained for gene editing technology. Development of SRG Platform begins; Completion of a 10,000 ft2 facility; Scientific team assembled with in vivo efficacy & toxicity capabilities.
SRG Platform validated and first tumor models & efficacy studies in the OncoRat; Begin offering In vivo toxicity studies in humanized liver mice.
2017
2018
Successful launch of the OncoRat and xenograft services. Key tumor model development VCaP & LNCaP prostate, H358 lung xenografts. First PDX model establishment in SRG.
Continued expansion of OncoRat applications in tumor models. Continue development of ImmunoRat & HepatoRat.
2019
2020
New gene editing technology Cas-CLOVER validated internally for cell line engineering reagents and services business, including editing of CHO cells for bioprocessing. Mike Schlosser, Ph.D., DABT with 30 years+ CRO and pharmaceutical development experience joins Hera as CEO.

Our Team

We have experienced management with over 70+ years of combined experience in the
preclinical research, gene editing and drug development space.

Michael Schlosser, Ph.D.,
Michael Schlosser, Ph.D.,Chief Executive Officer
Fallon Noto, Ph.D.
Fallon Noto, Ph.D.Executive Director, R&D/In Vivo Services
Chris Brenzel
Chris BrenzelSr. Director, Business Development/Gene Editing Solutions
Valeriya Steffey, M.D.
Valeriya Steffey, M.D.Director, In Vitro Services
Jack Crawford, M.S.
Jack Crawford, M.S.Strategic Adviser, Board of Directors
Goutham Narla, M.D., Ph.D.
Goutham Narla, M.D., Ph.D.SAB Member & Consultant
Diane Begemann, Ph.D.
Diane Begemann, Ph.D.Scientist, Study Director
Bisoye Towobola, DVM, M.S
Bisoye Towobola, DVM, M.SVeterinarian & Study Manager, In Vivo Services
Ashley Oldfield
Ashley OldfieldHead of Operations
This Could Be You
This Could Be You

Check our career page here